184 related articles for article (PubMed ID: 20072149)
1. Trisomy 11 in myelodysplastic syndromes defines a unique group of disease with aggressive clinicopathologic features.
Wang SA; Jabbar K; Lu G; Chen SS; Galili N; Vega F; Jones D; Raza A; Kantarjian H; Garcia-Manero G; McDonnell TJ; Medeiros LJ
Leukemia; 2010 Apr; 24(4):740-7. PubMed ID: 20072149
[TBL] [Abstract][Full Text] [Related]
2. Routine fluorescence in situ hybridization with the MLL probe does not reliably detect two separate signals on one chromosome 11 in patients with trisomy 11.
Smith A; Robson L; Heaps LS; Sharma P; Dunlop L; Bhave A; Bradstock K
Cancer Genet Cytogenet; 2001 Sep; 129(2):173-6. PubMed ID: 11566351
[TBL] [Abstract][Full Text] [Related]
3. Trisomy 11 as an isolated abnormality in acute myeloid leukemia is associated with unfavorable prognosis but not with an NPM1 or KIT mutation.
Alseraye FM; Zuo Z; Bueso-Ramos C; Wang S; Medeiros LJ; Lu G
Int J Clin Exp Pathol; 2011 Apr; 4(4):371-7. PubMed ID: 21577323
[TBL] [Abstract][Full Text] [Related]
4. Myelodysplastic syndromes with deletions of chromosome 11q lack cryptic MLL rearrangement and exhibit characteristic clinicopathologic features.
Wang SA; Abruzzo LV; Hasserjian RP; Zhang L; Hu Y; Zhang Y; Zhao M; Galili N; Raza A; Medeiros LJ; Garcia-Manero G; Miranda RN
Leuk Res; 2011 Mar; 35(3):351-7. PubMed ID: 20691474
[TBL] [Abstract][Full Text] [Related]
5. MLL gene amplification in acute myeloid leukemia and myelodysplastic syndromes is associated with characteristic clinicopathological findings and TP53 gene mutation.
Tang G; DiNardo C; Zhang L; Ravandi F; Khoury JD; Huh YO; Muzzafar T; Medeiros LJ; Wang SA; Bueso-Ramos CE
Hum Pathol; 2015 Jan; 46(1):65-73. PubMed ID: 25387813
[TBL] [Abstract][Full Text] [Related]
6. Tandem duplication of the MLL gene in myelodysplastic syndrome-derived overt leukemia with trisomy 11.
Yamamoto K; Hamaguchi H; Nagata K; Kobayashi M; Taniwaki M
Am J Hematol; 1997 May; 55(1):41-5. PubMed ID: 9136917
[TBL] [Abstract][Full Text] [Related]
7. IS THE AMPLIFICATION OF c-MYC, MLL AND RUNX1 GENES IN AML AND MDS PATIENTS WITH TRISOMY 8, 11 AND 21 A FACTOR FOR A CLONAL EVOLUTION IN THEIR KARYOTYPE?
Angelova S; Spassov B; Nikolova V; Christov I; Tzvetkov N; Simeonova M
Tsitol Genet; 2015; 49(3):25-32. PubMed ID: 26214902
[TBL] [Abstract][Full Text] [Related]
8. Double minute chromosomes in acute myeloid leukemia, myelodysplastic syndromes, and chronic myelomonocytic leukemia are associated with micronuclei, MYC or MLL amplification, and complex karyotype.
Huh YO; Tang G; Talwalkar SS; Khoury JD; Ohanian M; Bueso-Ramos CE; Abruzzo LV
Cancer Genet; 2016; 209(7-8):313-20. PubMed ID: 27318442
[TBL] [Abstract][Full Text] [Related]
9. Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML.
Schnittger S; Kinkelin U; Schoch C; Heinecke A; Haase D; Haferlach T; Büchner T; Wörmann B; Hiddemann W; Griesinger F
Leukemia; 2000 May; 14(5):796-804. PubMed ID: 10803509
[TBL] [Abstract][Full Text] [Related]
10. Duplication or amplification of chromosome band 11q23, including the unrearranged MLL gene, is a recurrent abnormality in therapy-related MDS and AML, and is closely related to mutation of the TP53 gene and to previous therapy with alkylating agents.
Andersen MK; Christiansen DH; Kirchhoff M; Pedersen-Bjergaard J
Genes Chromosomes Cancer; 2001 May; 31(1):33-41. PubMed ID: 11284033
[TBL] [Abstract][Full Text] [Related]
11. Trisomy 11 and a complex t(11;11;22) in a patient with acute myelomonocytic leukemia (AML-M4) following myelodysplasia (MDS): a cytogenetic study of a mechanism of leukemogenesis.
Bernasconi P; Cavigliano PM; Boni M; Malcovati L; Astori C; Castagnola C; Pagnucco G; Vanelli L; Calatroni S; Caresana M; Lazzarino M; Bernasconi C
Cancer Genet Cytogenet; 2000 Jan; 116(2):111-8. PubMed ID: 10640142
[TBL] [Abstract][Full Text] [Related]
12. Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML.
Takahashi K; Jabbour E; Wang X; Luthra R; Bueso-Ramos C; Patel K; Pierce S; Yang H; Wei Y; Daver N; Faderl S; Ravandi F; Estrov Z; Cortes J; Kantarjian H; Garcia-Manero G
Leukemia; 2013 Oct; 27(10):2081-3. PubMed ID: 23774633
[No Abstract] [Full Text] [Related]
13. Homogeneously staining region (hsr) on chromosome 11 is highly specific for KMT2A amplification in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
Sakhdari A; Tang Z; Ok CY; Bueso-Ramos CE; Medeiros LJ; Huh YO
Cancer Genet; 2019 Oct; 238():18-22. PubMed ID: 31425921
[TBL] [Abstract][Full Text] [Related]
14. Genetic analysis of dasatinib-treated chronic myeloid leukemia rapidly developing into acute myeloid leukemia with monosomy 7 in Philadelphia-negative cells.
Larsson N; Billström R; Lilljebjörn H; Lassen C; Richter J; Ekblom M; Fioretos T
Cancer Genet Cytogenet; 2010 Jun; 199(2):89-95. PubMed ID: 20471511
[TBL] [Abstract][Full Text] [Related]
15. Acute myeloid leukemia with trisomy 11: a molecular cytogenetic study.
Kwong YL; Wong KF
Cancer Genet Cytogenet; 1997 Nov; 99(1):19-23. PubMed ID: 9352791
[TBL] [Abstract][Full Text] [Related]
16. A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia.
Bacher U; Haferlach T; Kern W; Haferlach C; Schnittger S
Haematologica; 2007 Jun; 92(6):744-52. PubMed ID: 17550846
[TBL] [Abstract][Full Text] [Related]
17. A new recurrent translocation, t(5;11)(q35;p15.5), associated with del(5q) in childhood acute myeloid leukemia. The UK Cancer Cytogenetics Group (UKCCG).
Jaju RJ; Haas OA; Neat M; Harbott J; Saha V; Boultwood J; Brown JM; Pirc-Danoewinata H; Krings BW; Müller U; Morris SW; Wainscoat JS; Kearney L
Blood; 1999 Jul; 94(2):773-80. PubMed ID: 10397745
[TBL] [Abstract][Full Text] [Related]
18. Trisomy 11: prevalence among 22,403 unique patient cytogenetic studies and clinical correlates.
Caramazza D; Ketterling RP; Knudson RA; Hanson CA; Siragusa S; Pardanani A; Tefferi A
Leukemia; 2010 May; 24(5):1092-4. PubMed ID: 20357821
[No Abstract] [Full Text] [Related]
19. Monitoring of post-transplant MLL-PTD as minimal residual disease can predict relapse after allogeneic HSCT in patients with acute myeloid leukemia and myelodysplastic syndrome.
Kong J; Gao MG; Qin YZ; Wang Y; Yan CH; Sun YQ; Chang YJ; Xu LP; Zhang XH; Liu KY; Huang XJ; Zhao XS
BMC Cancer; 2022 Jan; 22(1):11. PubMed ID: 34979982
[TBL] [Abstract][Full Text] [Related]
20. Single nucleotide polymorphism array-based karyotyping in acute myeloid leukemia or myelodysplastic syndrome with trisomy 8 as the sole chromosomal abnormality.
Hahm C; Mun YC; Seong CM; Han SH; Chung WS; Huh J
Acta Haematol; 2013; 129(3):154-8. PubMed ID: 23208021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
